A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 156 (final count)
- Started
- Apr 2, 2018
- Main results expected
- May 2031
- Fully finished
- May 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Very Good Partial Response or Better Response Rate (VGPR)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Complete Response (CR) or Better Rate
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Time to Response (TTR)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Duration of Response (DOR)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Time to Progression (TTP)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Progression-Free Survival (PFS)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Overall Survival (OS)
Measured over: Up to approximately 3.5 years after the last participant is enrolled
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03314181 · record last updated 2025-08-14 · checked 2026-11-09 15:47 UTC